Table 4.
Lipid Levels, Blood Pressures, and Serum Creatinine After Placebo and Salsalate Therapy
| All Participants | Healthy Controls | Patients With Metabolic Syndrome | Patients With Atherosclerosis | |||||
|---|---|---|---|---|---|---|---|---|
| Placebo | Salsalate | Placebo | Salsalate | Placebo | Salsalate | Placebo | Salsalate | |
| LDL‐C, mmol/L | 2.39 (1.88 to 3.26) | 2.59 (2.03 to 3.33) | 3.00 (2.16 to 3.37) | 3.00 (2.40 to 3.33) | 3.0 (2.03 to 3.37) | 2.9 (1.88 to 3.33) | 1.89 (1.78 to 2.51) | 2.20 (1.94 to 2.79) |
| HDL‐C, mmol/L, | 1.16 (1.04 to 1.36) | 1.20 (0.96 to 1.34)* | 1.20 (0.96 to 1.34) | 1.34 (1.03 to 1.40)* | 1.11 (0.83 to 1.29) | 1.14 (1.06 to 1.29) | 1.14 (1.06 to 1.29) | 1.19 (1.14 to 1.29) |
| Triglycerides, mmol/L | 1.4 (0.8 to 1.8) | 1.1 (0.6 to 1.3)‡ | 0.9 (0.7 to 1.1) | 0.7 (0.5 to 0.9) | 1.8 (1.4 to 2.4) | 1.4 (1.0 to 2.2)* | 1.0 (0.8 to 1.8) | 0.6 (0.5 to 1.0)† |
| FFA, mmol/L | 0.48 (0.41 to 0.88) | 0.35 (0.30 to 0.66)† | 0.41 (0.40 to 0.74) | 0.32 (0.30 to 0.57) | 0.81 (0.53 to 0.96) | 0.57 (0.49 to 0.67)* | 0.37 (0.32 to 0.60) | 0.33 (0.27 to 0.39) |
| SBP, mm Hg | 126 (110 to 137) | 121 (114 to 137) | 115 (104 to 128) | 120 (109 to 134) | 133 (126 to 140) | 127 (118 to 140) | 132 (121 to 136) | 122 (118 to 134) |
| DBP, mm Hg | 72 (67 to 79) | 73 (69 to 83) | 69 (66 to 75) | 74 (69 to 83) | 76 (68 to 82) | 76 (72 to 84) | 73 (70 to 77) | 71 (67 to 81) |
| SCr, mmol/L | 0.87 (0.17) | 0.94 (0.21)‡ | 0.84 (0.19) | 0.89 (0.22) | 0.87 (0.17) | 0.91 (0.19) | 0.94 (0.12) | 1.06 (0.17) |
Data are presented as median (IQR). DBP indicates diastolic blood pressure; FFA, free fatty acids; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; SCr, serum creatinine.
*P<0.05; †P<0.01; ‡P<0.001.